Asset 1 (PROM101): First-in-class fully human depleting afucosylated¹ anti-ROR1 antibody

Description:  

• PROM101 is designed to induce ADCC, ADCP and CDC³ by binding the ROR1 receptor present on highly aggressive cancerous cells with high specificity.  
• PROM101 simultaneously activates Natural killer (NK) cells 
• PROM101 inhibits tumor cell proliferation, as well as induces ADCC to kill cancer cells.

Indications:  

• Solid tumors—PROM101 is effective in TNBC² with 56% of tumors having high levels of membrane ROR1, followed by ovarian cancers and lung adenocarcinomas.  
• Liquid Tumors--Relapsed or Refractory CLL, MCL and SLL⁴

Clinical Status: 
‍

IND for Phase 0 clinical study in solid tumors approved by the FDA.  The clinical study in the United States Sites has started and will be completed in the next 6 months.

Asset 2 (PROM202):  Best-in-class fully human dual activity afucosylated¹ Anti-GARP/TGFB1 antibody 

Description

• PROM202 is designed to induce killing of tumor-cells directly through ADCC of GARP-positive tumor cells.
• PROM202 blocks TGFB1 release from GARP/TGFB1 complex within cancer microenvironment inhibiting the host’s T cell immunosuppression.

Indications:

• Solid tumors: OVAC⁴, lung carcinoma, CRC, breast cell carcinoma are all within the potential indications. GARP-expression is well-correlated with poor prognosis.  

Clinical Status:
‍

IND for Phase 0 clinical study in solid tumors approved by the FDA.  The clinical study In the United States Sites has started and will be completed in the next 6 months.